Patents by Inventor Mukesh K. Nyati

Mukesh K. Nyati has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Synthesis of EGFR Modulators
    Publication number: 20240018144
    Abstract: Provided herein are processes for synthesizing compounds useful as EGFR modulators.
    Type: Application
    Filed: October 12, 2021
    Publication date: January 18, 2024
    Inventors: Jason Christopher Rech, Mukesh K. Nyati, Fan Fang, Lei Zhang, Julian Paul Henschke
  • INHIBITORS OF EGFR, KRAS, BRAF, AND OTHER TARGETS AND USE OF THE SAME
    Publication number: 20230097789
    Abstract: Provided herein are compounds that are useful in treating cancer.
    Type: Application
    Filed: March 5, 2021
    Publication date: March 30, 2023
    Inventors: Mukesh K. Nyati, Theodore S. Lawrence, Christopher Whitehead, Jason Christopher Rech, Brennan Taylor Watch, Alexander Bridges
  • INHIBITORS OF EGFR, KRAS, BRAF, AND OTHER TARGETS AND USE OF THE SAME
    Publication number: 20230098205
    Abstract: Provided herein are compounds that are useful in treating cancer.
    Type: Application
    Filed: March 5, 2021
    Publication date: March 30, 2023
    Inventors: Mukesh K. Nyati, Alexander Bridges, Jason Christopher Rech, Brennan Taylor Watch
  • EGFR DIMER DISRUPTORS AND USE OF THE SAME
    Publication number: 20220340572
    Abstract: Provided herein are compounds that modulate EGFR and methods of using the same, for example to treat cancer.
    Type: Application
    Filed: May 9, 2022
    Publication date: October 27, 2022
    Inventors: Mukesh K. Nyati, Theodore S. Lawrence, Christopher Whitehead, Jason Christopher Rech, Brennan Taylor Watch
  • METHOD OF TREATING KRAS-ASSOCIATED CANCERS
    Publication number: 20220273643
    Abstract: Disclosed are methods of treating cancer characterized by expression of at least one KRAS mutation, using a compound of Formula I, below, or a pharmaceutically acceptable salt thereof, or a prodrug thereof: (I) Also disclosed are methods of altering the level of KRAS or cMet in a cell characterized by expression of at least a KRAS mutation with the compound of Formula I.
    Type: Application
    Filed: August 20, 2020
    Publication date: September 1, 2022
    Inventor: Mukesh K. Nyati
  • EGFR dimer disruptors and use of the same
    Patent number: 11358965
    Abstract: Provided herein are compounds that modulate EGFR and methods of using the same, for example to treat cancer.
    Type: Grant
    Filed: February 25, 2019
    Date of Patent: June 14, 2022
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Mukesh K. Nyati, Theodore S. Lawrence, Christopher Whitehead, Jason Christopher Rech, Brennan Taylor Watch
  • EGFR DIMER DISRUPTORS AND USE OF THE SAME
    Publication number: 20200377503
    Abstract: Provided herein are compounds that modulate EGFR and methods of using the same, for example to treat cancer.
    Type: Application
    Filed: February 25, 2019
    Publication date: December 3, 2020
    Inventors: Mukesh K. Nyati, Theodore S. Lawrence, Christopher Whitehead, Jason Christopher Rech, Brennan Taylor Watch
  • Inhibitors of the Epidermal Growth Factor Receptor- Heat Shock Protein 90 Binding Interaction
    Publication number: 20150218277
    Abstract: Provided herein are compounds that inhibit a binding interaction between an epidermal growth factor receptor (EGFR) and a heat shock protein 90 (HSP90), as well as compositions, e.g., pharmaceutical compositions, comprising the same, and related kits. In some embodiments, the compound is an antibody or antibody analog, and, in other embodiments, the compound is a peptide or peptide analog. Also provided are methods of using the compounds, including methods of increasing degradation of an EGFR, methods of treating cancer, and methods of sensitizing tumors to radiation therapy.
    Type: Application
    Filed: April 23, 2015
    Publication date: August 6, 2015
    Inventors: Mukesh K. Nyati, Theodore S. Lawrence
  • Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
    Patent number: 9029502
    Abstract: Provided herein are compounds that inhibit a binding interaction between an epidermal growth factor receptor (EGFR) and a heat shock protein 90 (HSP90), as well as compositions, e.g., pharmaceutical compositions, comprising the same, and related kits. In some embodiments, the compound is an antibody or antibody analog, and, in other embodiments, the compound is a peptide or peptide analog. Also provided are methods of using the compounds, including methods of increasing degradation of an EGFR, methods of treating cancer, and methods of sensitizing tumors to radiation therapy.
    Type: Grant
    Filed: December 19, 2011
    Date of Patent: May 12, 2015
    Assignee: The Regents of the University of Michigan
    Inventors: Mukesh K. Nyati, Theodore S. Lawrence
  • INHIBITORS OF THE EPIDERMAL GROWTH FACTOR RECEPTOR-HEAT SHOCK PROTEIN 90 BINDING INTERACTION
    Publication number: 20120190622
    Abstract: Provided herein are compounds that inhibit a binding interaction between an epidermal growth factor receptor (EGFR) and a heat shock protein 90 (HSP90), as well as compositions, e.g., pharmaceutical compositions, comprising the same, and related kits. In some embodiments, the compound is an antibody or antibody analog, and, in other embodiments, the compound is a peptide or peptide analog. Also provided are methods of using the compounds, including methods of increasing degradation of an EGFR, methods of treating cancer, and methods of sensitizing tumors to radiation therapy.
    Type: Application
    Filed: December 19, 2011
    Publication date: July 26, 2012
    Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Mukesh K. Nyati, Theodore S. Lawrence